RELATIVE PROGRESSION-FREE SURVIVAL OVER TIME OF NOVEL TRIPLET REGIMENS FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Betts, K. [1 ]
Chen, C. [2 ]
Zichlin, M. [1 ]
Brun, A. [2 ]
Signorovitch, J. [1 ]
Makenbaeva, D. [2 ]
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Bristol Myers Squibb Inc, Plainsboro, NJ USA
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1300
引用
收藏
页码：533 / 533
页数：1
相关论文
共 50 条
  • [1] Relative Progression-Free Survival Over Time with Novel Triplet Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma
    Betts, Keith A.
    Chen, Clara
    Zichlin, Miriam L.
    Brun, Alexander
    Signorovitch, James E.
    Makenbaeva, Dinara
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S334 - S335
  • [2] Daratumumab Improves Progression-Free Survival in Relapsed/Refractory Myeloma
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (11) : 915 - 915
  • [3] Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos, Meletios
    Sonneveld, Pieter
    Manier, Salomon
    Lam, Annette
    Roccia, Tito
    Schecter, Jordan M.
    Cost, Patricia
    Pacaud, Lida
    Poirier, Abbey
    Tremblay, Gabriel
    Lan, Tommy
    Valluri, Satish
    Kumar, Shaji
    BMC CANCER, 2024, 24 (01)
  • [4] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M.
    Sonneveld, P.
    Nahi, H.
    Kumar, S.
    Hashim, M.
    Kulakova, M.
    Duran, M.
    Heeg, B.
    Lam, A.
    Dearden, L.
    VALUE IN HEALTH, 2017, 20 (09) : A408 - A408
  • [5] Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
    M A Dimopoulos
    M Hussein
    A S Swern
    D Weber
    Leukemia, 2011, 25 : 1620 - 1626
  • [6] Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos, M. A.
    Hussein, M.
    Swern, A. S.
    Weber, D.
    LEUKEMIA, 2011, 25 (10) : 1620 - 1626
  • [7] Recent Results of the ELOQUENT-3 Study Relapsed and refractory Multiple Myeloma: Doubling of progression-free Survival under the Elotuzumab Triplet
    Thaesler, Elke
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (12) : 692 - 693
  • [8] Progression-Free Survival Efficacy in Refractory/Relapsed Multiple Myeloma among Elderly Patients: A Systematic Review
    Yang, Tung-Lung
    Lin, Chin
    Ho, Ching-Liang
    Huang, Tzu-Chuan
    Wu, Yi-Ying
    Jhou, Hong-Jie
    Chen, Po-Huang
    Lee, Cho-Hao
    LIFE-BASEL, 2023, 13 (12):
  • [9] Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime
    Hardi, Apor
    Varga, Gergely
    Nagy, Zsolt
    Kosztolanyi, Szabolcs
    Varoczy, Laszlo
    Plander, Mark
    Schneider, Tamas
    Demeter, Judit
    Alizadeh, Hussain
    Illes, Arpad
    Masszi, Tamas
    Mikala, Gabor
    ORVOSI HETILAP, 2021, 162 (36) : 1451 - 1458
  • [10] Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma
    Yan, Xiaoyu
    Xu, Xu Steven
    Weisel, Katja C.
    Mateos, Maria-Victoria
    Sonneveld, Pieter
    Dimopoulos, Meletios A.
    Usmani, Saad Zafar
    Bahlis, Nizar J.
    Puchalski, Thomas
    Ukropec, Jon
    Bellew, Kevin
    Ming, Qi
    Sun, Steven
    Zhou, Honghui
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (06): : 1345 - 1354
12345